Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Performance of a Divided-Load Intravenous Vancomycin Dosing Strategy for Obese Patients

View through CrossRef
Background: Current guidelines recommend vancomycin trough concentrations of 15 to 20 µg/mL in complicated infections and all trough concentrations >10 µg/mL to avoid developing microbial resistance. To date, no published protocol reliably meets these recommendations for obese patients. Objective: We assessed the performance of a novel, obese-specific, divided-load vancomycin protocol for attaining target trough concentrations within 12 to 24 hours of dosing initiation, and during maintenance dosing, in obese patients. Methods: The protocol was evaluated through prospective medical record review in 54 consecutive obese patients. Vancomycin serum concentrations were drawn before the third and fifth dose after initiation. Steady-state concentrations were drawn after the third dose once maintenance dosing was achieved and periodically thereafter. Results: Within 12 hours after dosing initiation, 48 (89%) study patients exhibited trough concentrations of 10 to 20 µg/mL averaging 14.5 ± 3.2 µg/mL; 51 (94%) study patients exhibited trough concentrations >10 µg/mL within 12 hours after dosing initiation, and 3 (6%) had trough concentrations >20 µg/mL. Thirty-one participants had second trough concentrations drawn within 24 hours of dosing initiation, averaging 15.0 ± 3.1 µg/mL; 24 patients had a total of 32 trough concentrations drawn during maintenance dosing, averaging 15.1 ± 2.5 µg/mL. Conclusion: Obese-specific, divided-load dosing achieved trough concentrations of 10 to 20 µg/mL for 89% of obese patients within 12 hours of initial dosing and 97% of obese patients within 24 hours of initial dosing while preventing doses given during supratherapeutic trough levels; 97% of troughs measured during steady state were within target range.
Title: Performance of a Divided-Load Intravenous Vancomycin Dosing Strategy for Obese Patients
Description:
Background: Current guidelines recommend vancomycin trough concentrations of 15 to 20 µg/mL in complicated infections and all trough concentrations >10 µg/mL to avoid developing microbial resistance.
To date, no published protocol reliably meets these recommendations for obese patients.
Objective: We assessed the performance of a novel, obese-specific, divided-load vancomycin protocol for attaining target trough concentrations within 12 to 24 hours of dosing initiation, and during maintenance dosing, in obese patients.
Methods: The protocol was evaluated through prospective medical record review in 54 consecutive obese patients.
Vancomycin serum concentrations were drawn before the third and fifth dose after initiation.
Steady-state concentrations were drawn after the third dose once maintenance dosing was achieved and periodically thereafter.
Results: Within 12 hours after dosing initiation, 48 (89%) study patients exhibited trough concentrations of 10 to 20 µg/mL averaging 14.
5 ± 3.
2 µg/mL; 51 (94%) study patients exhibited trough concentrations >10 µg/mL within 12 hours after dosing initiation, and 3 (6%) had trough concentrations >20 µg/mL.
Thirty-one participants had second trough concentrations drawn within 24 hours of dosing initiation, averaging 15.
0 ± 3.
1 µg/mL; 24 patients had a total of 32 trough concentrations drawn during maintenance dosing, averaging 15.
1 ± 2.
5 µg/mL.
Conclusion: Obese-specific, divided-load dosing achieved trough concentrations of 10 to 20 µg/mL for 89% of obese patients within 12 hours of initial dosing and 97% of obese patients within 24 hours of initial dosing while preventing doses given during supratherapeutic trough levels; 97% of troughs measured during steady state were within target range.

Related Results

S5. DOES THE TIME OF DRUG ADMINISTRATION ALTER THE ADVERSE EVENT RISK OF LURASIDONE?
S5. DOES THE TIME OF DRUG ADMINISTRATION ALTER THE ADVERSE EVENT RISK OF LURASIDONE?
Abstract Background Lurasidone is once a day oral medication, which could be administered any time of the day, but the relations...
In Vitro Assessment of Vancomycin HCl Compatibility after Coinfusion with a Specialized Amino Acid Formulation
In Vitro Assessment of Vancomycin HCl Compatibility after Coinfusion with a Specialized Amino Acid Formulation
Vancomycin usage at British Columbia's Children's Hospital has increased substantially in the Special Care Nursery as a consequence of a study demonstrating a reduced morbidity and...
2109. Liposomal Amphotericin B-associated Nephrotoxicity in Obese and Non-obese Patients
2109. Liposomal Amphotericin B-associated Nephrotoxicity in Obese and Non-obese Patients
Abstract Background Liposomal amphotericin B (L-amb) is an important antifungal agent which exhibits significant rates of dose-d...
Immune-Mediated Thrombocytopenia in Patients Treated with Vancomycin.
Immune-Mediated Thrombocytopenia in Patients Treated with Vancomycin.
Abstract Numerous drugs are known to cause immune thrombocytopenia (TP) mediated by antibodies (abs) that bind to platelets only when the sensitizing drug is present...

Back to Top